Uploaded June 2026 | Updated September 2026, 2 days ago
Managed early-access schemes—that give some patients medicines with early signs of promise before they have market authorisation—are gaining traction but complexities around ethics, regulation, evidence and cost can delay or limit uptake. For patients the test is whether these models speed up access and outcomes. For innovators the test is whether they deliver return on investment in research and development. For health-system executives the test is financial sustainability. Which schemes have delivered tangible benefits? How can contracts balance payer caution with patient urgency?
Managed early-access schemes—that give some patients medicines with early signs of promise before they have market authorisation—are gaining traction but complexities around ethics, regulation, evidence and cost can delay or limit uptake. For patients the test is whether these models speed up access and outcomes. For innovators the test is whether they deliver return on investment in research and development. For health-system executives the test is financial sustainability. Which schemes have delivered tangible benefits? How can contracts balance payer caution with patient urgency?
